Ana Sofia Rios

Ana Sofia Rios

Auto-generated profile, based on publicly available information

Ana Sofia Rios

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Neurologie mit Experimenteller Neurologie Germany (A.S.R., U.T., A.A.K., K.V., M.B., T.R., A.H.N., P.S.S., T.G.L., C.O., M.E., A.K.).

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2023 in Medical Image Analysis
Verified
Journal Article
Open access
SOSimón Oxenford
Simón Oxenford
ARAna Sofía Ríos
Ana Sofía Ríos
BHBarbara Hollunder
Barbara Hollunder
CNClemens Neudorfer
Clemens Neudorfer
ABAlexandre Boutet
Alexandre Boutet
Andreas HornAndreas Horn
Andreas Horn
Spatial normalization-the process of mapping subject brain images to an average template brain-has evolved over the last 20+ years into a reliable method that facilitates the comparison of brain imaging results across patients, centers & modalities. While overall successful, sometimes, this automatic process yields suboptimal results, especially when dealing with brains with extensive neurodegeneration and atrophy patterns, or when high accuracy in specific regions is needed. Here we introduce WarpDrive, a novel tool for manual refinements of image alignment after automated registration. We show that the tool applied in a cohort of patients with Alzheimer's disease who underwent deep brain stimulation surgery helps create more accurate representations of the data as well as meaningful models to explain patient outcomes. The tool is built to handle any type of 3D imaging data, also allowing refinements in high-resolution imaging, including histology and multiple modalities to precisely aggregate multiple data sources together.

7 June 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
IRIda Rangus
Ida Rangus
ARAna Sofia Rios
Ana Sofia Rios
AHAndreas Horn
Andreas Horn
MFMerve Fritsch
Merve Fritsch
AKAhmed Khalil
Ahmed Khalil
CNChristian H. Nolte
Christian H. Nolte
Thalamic aphasia results from focal thalamic lesions that cause dysfunction of remote but functionally connected cortical areas due to language network perturbation. However, specific local and network-level neural substrates of thalamic aphasia remain incompletely understood. Using lesion symptom mapping, we demonstrate that lesions in the left ventrolateral and ventral anterior thalamic nucleus are most strongly associated with aphasia in general and with impaired semantic and phonemic fluency and complex comprehension in particular. Lesion network mapping (using a normative connectome based on fMRI data from 1000 healthy individuals) reveals a Thalamic aphasia network encompassing widespread left-hemispheric cerebral connections, with Broca’s area showing the strongest associations, followed by the superior and middle frontal gyri, precentral and paracingulate gyri, and globus pallidus. Our results imply the critical involvement of the left ventrolateral and left ventral anterior thalamic nuclei in engaging left frontal cortical areas, especially Broca’s area, during language processing.

1 September 2025 in Stroke
Verified
Journal Article
Closed access
ARAna Sofía Ríos
Ana Sofía Ríos
UTUchralt Temuulen
Uchralt Temuulen
AKAhmed A. Khalil
Ahmed A. Khalil
KVKersten Villringer
Kersten Villringer
HAHuma Fatima Ali
Huma Fatima Ali
AKAnna Kufner
Anna Kufner
BACKGROUND: Poststroke depression affects up to one-third of stroke survivors, significantly impacting recovery and quality of life. However, its pathophysiology remains unclear. METHODS: We analyzed 2 independent, prospective ischemic stroke cohorts (PROSCIS-B [Prospective Cohort of Incident Stroke Berlin] and BAPTISe [Biomarkers and Perfusion-Training-Induced Changes After Stroke]; n=377) enrolled at the Charité Hospital, Germany, to identify brain regions and networks associated with depressive symptoms poststroke. Lesion-symptom mapping assessed associations between lesion location and depressive symptoms measured by the Center for Epidemiological Studies Depression Scale at 6 (BAPTISe) or 12 (PROSCIS-B) months poststroke. Lesion-network mapping evaluated lesion connectivity with brain networks. A mixed-effects model, including cohort as a random effect, assessed the relationship between network similarity (Pearson correlation) and Center for Epidemiological Studies Depression Scale scores. Dice coefficients (DC) quantified spatial overlap with canonical resting-state networks. RESULTS: Lesion-symptom mapping showed no significant associations between lesion location and depressive symptoms. In contrast, lesion-network mapping revealed that lesion connectivity to brain regions including the frontal pole, middle and inferior frontal gyri, inferior temporal gyrus, supramarginal gyrus, angular gyrus, frontal orbital cortex, and thalamus weakly correlated with Center for Epidemiological Studies Depression Scale scores (β, 11.4 [95%CI, 1.8–21.1]; P =0.02). These regions overlapped with the frontoparietal (DC=0.28), salience (DC=0.27), and default mode (DC=0.20) networks, as well as a published depression circuit (DC=0.43). However, these findings did not replicate across data sets. CONCLUSIONS: Lesion location alone was not associated with poststroke depression. However, connectivity-based analyses implicated disruption of large-scale brain networks in the development of depressive symptoms. The failure to validate this association across data sets underscores the need for further studies with more comparable patient populations—particularly in terms of stroke severity and harmonized assessment time-points—to confirm these findings and their clinical relevance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01363856. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01954797.

11 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PRPaula Roesen
Paula Roesen
UTUchralt Temuulen
Uchralt Temuulen
ARAna Sofia Rios
Ana Sofia Rios
RGRamanan Ganeshan
Ramanan Ganeshan
TBTim Bastian Braemswig
Tim Bastian Braemswig
AKAnna Kufner
Anna Kufner
Background: Cerebral small vessel disease (CSVD) is a common incidental finding on cerebral MRI in patients with transient ischemic attack (TIA) and stroke and has been linked to increased cerebrovascular risk and cognitive decline. This study aimed to investigate the prevalence of CSVD imaging biomarkers in TIA patients and evaluate their association with cognitive function over three years following the ischemic event. Methods: A cohort of 246 TIA patients from the INSPiRE-TMS (ClinicalTrials.gov: NCT01586702 ) study were included. The CSVD-score – including white matter hyperintensities (WMH), lacunes, cerebral microbleeds (CMBs), and enlarged perivascular spaces (PVS) – was assessed on baseline MRI. Cognitive performance was assessed via the Montreal Cognitive Assessment (MoCA) at baseline and annual outpatient visits up to 3 years. Results: CSVD was present in 58.5% of TIA patients. The most prevalent imaging biomarker was lacunes (36.6%), followed by PVS (28.1%), WMH (19.5%) and CMBs (17.9%). Cumulative CSVD-score (range 0-4) was an independently associated with cognitive decline up to 3 years (β = -0.53, 95% CI -0.97 – -0.09, p = 0.018), alongside advanced age (β = -0.08, 95% CI -0.13 – -0.03, p=0.001). CMB burden was the strongest predictive component of the CSVD-score (β = 0.42, 95% CI -0.63 – -0.21, p < 0.001). Specifically, CSVD-score had a significant negative effect on the memory domain of cognitive function with an adjusted β of - 0.18 (95% CI -0.32 – -0.04, p = 0.014). Conclusion: Imaging biomarkers of CSVD are present in more than half of TIA patients and are an independent predictor of cognitive decline up to 3 years, with the strongest effect on the memory domain of cognitive function. Whether the presence of CMBs is the strongest predictive imaging biomarker of cognitive decline in TIA patients requires confirmation in further studies.

11 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ASAlina Stegemann
Alina Stegemann
ARAna Sofia Rios
Ana Sofia Rios
AKAhmed Khalil
Ahmed Khalil
UGUlrike Grittner
Ulrike Grittner
UTUchralt Temuulen
Uchralt Temuulen
MEMatthias Endres
Matthias Endres
Background Post-stroke pain (PSP) affects nearly half of stroke survivors, severely compromising quality of life. The causes of PSP remain underexplored, although there is likely a complex interplay of lesion effects, psychological factors and mobility that play a role in the development of PSP. The aim of the study was to investigate clinical characteristics associated with PSP, as well as structural and functional correlates of PSP using lesion symptom (LSM) and network mapping (LNM). Methods We analyzed data from the INSPiRE-TMS cohort, encompassing 1,022 minor ischemic stroke patients. Pain severity and psychological factors (EQ5D-3L questionnaire) were assessed annually for up to 3 years. In a sub-group of 391 patients with available imaging data, LSM and LNM analyses were conducted to identify neural correlates of PSP. Results Overall, 47% of patients reported pain 1-year post-stroke. Multivariable regression analyses identified baseline anxiety as being associated with PSP assessed at 1-year post-stroke (OR 2.90, 95% CI 1.17–7.17, p=0.021). LSM did not identify any voxels associated with new severe pain. LNM identified a network involving anterior cingulate cortex, thalamus and insular cortex. Adjusting for anxiety highlighted distinct network contributions, suggesting interactive effects of psychological states on pain perception. Automated comparison to large metanalytical findings using Neurosynth associated the terms ‘pain’ and ‘nociception’ most strongly to the identified network. Conclusion PSP is closely associated with psychological factors such as anxiety. LNM of PSP revealed disruptions in a pain-related neural network consistent with prior pain research. These results warrant external validation and could guide future network-targeted neuromodulation therapies. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01586702.